ALNY · XBRL financial data

Alnylam Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALNY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	493	844	1,037	—	—	—
Revenue from contracts with customers	493	844	1,037	1,828	2,248	3,714
Cost of goods and services sold	78	115	140	268	307	677
Research and development	655	792	883	1,004	1,126	1,320
Selling, general and administrative	588	621	771	796	976	1,211
Operating income (loss)	(828)	(709)	(785)	(282)	(177)	502
Interest income	12	2	25	96	122	111
Interest expense	84	143	156	121	142	253
Other income (expense)	46	(2)	(109)	(126)	(181)	5
Income tax expense (benefit)	3	1	4	7	(99)	9
Net income (loss)	(858)	(853)	(1,131)	(440)	(278)	314
Earnings per share, basic USD per share	(7.46)	(7.20)	(9.30)	(3.52)	(2.18)	2.39
Earnings per share, diluted USD per share	(7.46)	(7.20)	(9.30)	(3.52)	(2.18)	2.33
Weighted average shares, basic millions of shares	115	118	122	125	128	131
Weighted average shares, diluted millions of shares	115	118	122	125	128	135

Fiscal years (ALNY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	497	820	866	813	966	1,657
Marketable securities	1,333	1,549	1,298	1,616	1,720	1,251
Accounts receivable	102	199	238	328	405	778
Inventory	75	86	129	89	79	83
Prepaid and other current assets	63	88	133	126	117	282
Total current assets	2,615	2,809	2,692	2,983	3,295	4,051
Property and equipment, net	465	502	523	526	503	513
Right-of-use asset	241	232	215	200	191	195
Total assets	3,407	3,643	3,546	3,830	4,240	4,966
Accounts payable	52	73	98	56	88	116
Accrued liabilities	356	395	545	713	887	1,080
Total current liabilities	585	696	768	968	1,186	1,466
Lease liability, non-current	293	281	261	243	230	225
Total liabilities	2,391	3,055	3,705	4,051	4,173	4,177
Accumulated deficit	(4,585)	(5,438)	(6,569)	(7,010)	(7,288)	(6,703)
Total stockholders' equity	1,016	588	(158)	(221)	67	789
Total liabilities and equity	3,407	3,643	3,546	3,830	4,240	4,966
Common shares outstanding (cover page) millions of shares	117	120	124	126	129	133

Fiscal years (ALNY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(858)	(853)	(1,131)	(440)	(278)	314
Stock-based compensation	140	166	231	222	272	348
Net cash from operating activities	(615)	(642)	(541)	104	(8)	524
Purchases of property and equipment	70	76	72	62	34	59
Net cash from investing activities	(436)	(273)	169	(336)	(117)	436
Proceeds from issuing common stock	0	0	—	—	—	—
Net cash from financing activities	995	1,247	426	172	294	(305)
Net change in cash	(51)	323	46	(54)	154	690

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Alnylam Pharmaceuticals	1,754	1,458	341*	133.9M	Q3 FY26 10-QSep 30, 2026
Idexx Laboratories	198	1,214	450*	78.8M	Q3 FY26 10-QSep 30, 2026
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Zoetis	1,476	2,468	655*	413.2M	Q2 FY26 10-QJun 30, 2026
INSMED	397	524	(36)*	219.4M	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	Q3 FY26 10-QSep 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.